121 related articles for article (PubMed ID: 32201130)
1. Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.
England JT; Saini L; Hogge D; Forrest D; Narayanan S; Power M; Nevill T; Kuchenbauer F; Hudoba M; Szkotak A; Brandwein J; Sanford D
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e427-e436. PubMed ID: 32201130
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
3. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
[TBL] [Abstract][Full Text] [Related]
4. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients.
El Gammal MM; Owaidat HM; Rashed RA; Fatah RA; Samra MA
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e406-e413. PubMed ID: 31031147
[TBL] [Abstract][Full Text] [Related]
6. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
7. [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
Jia JS; Yang SM; Wang J; Jiang H; Zhao T; Bao L; Shi HX; Lu J; Zhu HH; Lai YY; Jiang B; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):497-502. PubMed ID: 27431075
[TBL] [Abstract][Full Text] [Related]
8. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors.
Thomas X; Le QH; Danaïla C; Lhéritier V; Ffrench M
Leuk Res; 2002 Oct; 26(10):909-18. PubMed ID: 12163052
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.
Olson AL; Saliba RM; Oran B; Chen J; Alousi A; Ahmed S; Bashir Q; Ciurea SO; Hosing C; Seon Im J; Kebriaei P; Khouri IF; Mehta R; Nieto Y; Parmar S; Rezvani K; Shah N; Shpall E; Srour SA; Qazilbash M; Andersson BS; Champlin R; Popat UR
Acta Haematol; 2021; 144(1):74-81. PubMed ID: 32604096
[TBL] [Abstract][Full Text] [Related]
11. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
[TBL] [Abstract][Full Text] [Related]
12. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.
Souto Filho JT; Loureiro MM; Pulcheri W; Morais JC; Nucci M; Portugal RD
Diagn Pathol; 2015 Jul; 10():122. PubMed ID: 26205005
[TBL] [Abstract][Full Text] [Related]
14. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Coccia PF; Bleyer WA; Lukens JN; Siegel SE; Sather HN; Hammond GD
J Clin Oncol; 1989 Dec; 7(12):1807-15. PubMed ID: 2685179
[TBL] [Abstract][Full Text] [Related]
15. [A new prognostic stratification for patients with acute myeloid leukemia].
Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Ofran Y; Leiba R; Ganzel C; Saban R; Gatt M; Ram R; Arad A; Bulvik S; Hellmann I; Gino-Moor S; Zuckerman T; Hoffman R; Horowitz N; Lavi N; Ringelstein S; Henig I; Hayun M; Rowe JM
Am J Hematol; 2015 Dec; 90(12):1159-64. PubMed ID: 26435038
[TBL] [Abstract][Full Text] [Related]
17. Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Taparia M; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Mirza I; Quest G; Nahirniak S; Ghosh S; Sandhu I
Leuk Res; 2016 Jun; 45():47-52. PubMed ID: 27092851
[TBL] [Abstract][Full Text] [Related]
18. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.
Covut F; Gupta D; Pinto R; Dambrosio N; El Jurdi N; Meyerson H; Ueda M; Kolk M; Creger R; Metheny L; Cooper BW; Caimi PF; Malek E; Otegbeye F; Lazarus HM; De Lima M; Tomlinson BK
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):73-82. PubMed ID: 30528848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]